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Background: Translating knowledge derived from medical research into the clinical setting is dependent on the
representativeness of included patients. Therefore we compared baseline data of patients included in a recent large
study addressing young stroke in comparison to a large representative stroke registry.
Methods: We analysed baseline data of 5023 patients (age 18-55 years) with an acute cerebrovascular event
included in the sifap1 (Stroke in Young Fabry Patients) study. For comparison 17007 stroke patients (age 18-55 years)
documented (2004-2010) in a statutory stroke registry of the Institute of Quality Assurance Hesse of the Federal
State of Hesse (GQH), Germany.
Results: Among 17007 juvenile (18-55 years) patients identified in the GQH registry 15997 had an ischaemic stroke
or TIA (91%) or an intracranial haemorrhage (9%). In sifap1 5023 subjects were included. Sex distribution was
comparable (men: 59% sifap1 versus 60.5% GQH) whereas age differed between the groups: median age was
46 years in sifap1 versus 49 years in GQH. Slightly higher percentages for diabetes mellitus and hypertension in the
GQH registry were noted. There were no differences in stroke severity as assessed by NIHSS (median 3) and mRS
(median 2). In patients with ischaemic stroke or TIA (n = 4467 sifap1; n = 14522 GQH) higher rates of strokes due to
small artery occlusion and atherosclerosis occurred in older age groups; cardioembolism and strokes of other
determined cause occurred more frequently in younger patients.
Conclusions: The comparison of baseline characteristics between the sifap1 study and the GQH registry revealed
differences mainly determined by age.
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Evidence-based medicine is crucial to facilitate appropri-
ate decisions in patient care. It relies on clinical trials,
cohort studies, case-control studies, case series, and ob-
servational studies. However, different sources of bias
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unless otherwise stated.often discussed confounders is selection bias, which oc-
curs when considering patients for inclusion in a study
[1]. Potential reasons for selection bias are strict inclu-
sion criteria determining selected patient-groups, which
constitutes only a non-representative proportion of
patients of the broad spectrum in the delivery of care
[1]. In this context, translating knowledge derived
from clinical trials and observational studies into the
clinical setting is dependent on the representativeness
of the patients included in studies in comparison to
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single- or multi-centre design has been published. These
studies brought valuable data on age and gender distri-
bution, risk factors, etiologic factors, and imaging find-
ings on young stroke patients [2-6]. However, it is
crucial to address whether such data are identical with
what is seen in daily clinical practice before adapting
their conclusions to clinical practice. In this context it is
important to consider possible differences between data
derived from multinational projects in comparison with
nation-wide data collections [2,3].
For this reason, we analysed baseline data of patients
included in the recent largest observational young stroke
study, namely the sifap1 study and compared with the
Hesse Stroke Registry’s data on young stroke patients.
Due to the selection process when searching for eligible
patients within a general population of reference, dif-
ferences in baseline characteristics between the two
groups could be expected. The nature of the sifap1 study
(screening for a rare disease among young strokes) might
be a relevant determinant factor.
Methods
For the analysis two comprehensive prospective stroke
populations including young patients (18-55 years) were
analysed: (1) sifap1 study and (2) Register data of the
Institute of Quality Assurance Hesse (Geschäftsstelle für
Qualitätssicherung, GQH) [7,8]. For comparing baseline
characteristics the following parameters were consid-
ered: sex, age, previous cerebrovascular event, vascular
risk factors such as hypertension, diabetes mellitus and
current smoking, as well as stroke subtypes according to
the Trial of Org 10172 in Acute Stroke Treatment criteria
(TOAST) and the stroke severity as assessed by National
Institutes of Health Stroke Scale (NIHSS) and modified
Rankin Scale (mRS) [9]. In the sifap1 study the NIHSS was
determined within 48 h after admission; in GQH the
NIHSS was assessed on admission while the mRS was de-
termined one day after admission. 65.7% of the patients in-
cluded in the sifap1 study are German in origin and 74%
derive from German-speaking countries. The protocol for
the analysis of the study was reviewed and approved by the
ethical committee of the University of Giessen.
sifap1
The sifap1 study was a prospective multicentre European
observational study that aimed to establish the prevalence
of Fabry disease in 5023 young patients with a cerebrovas-
cular event (CVE). Patients were recruited between April
2007 and January 2010 at 47 centres in 15 European coun-
tries. Inclusion criteria were CVE <3 months prior to en-
rolment, age 18 to 55 years, and cerebral MRI ≤1 month of
inclusion (Table 1). TIA was defined as a CVE with clinical
symptoms lasting <24 hours.Besides genetic issues the study protocol directed a de-
tailed documentation of parameters such as vascular risk
factors, stroke severity, laboratory values, and results of
the diagnostic work up. All patients or their legal repre-
sentatives provided written informed consent. The study
was performed according to the Helsinki Declaration
and has been approved by all local ethical committees of
the participating centres [2,7].
GQH
The GQH database is an obligatory federal-state-wide
hospital-based registry that covers more than 95% of all
ischaemic strokes, transient ischaemic attacks (TIA) and
intracerebral haemorrhages in a community of more
than 6 million inhabitants of the Federal State of Hesse
(Germany). TIA was defined as a CVE with clinical
symptoms lasting <24 hours. The GQH-data include
various parameters of acute in-patient care, as well as
factors proved to be relevant for the course and the
prognosis of stroke. The acquisition of data for quality
assurance reasons is regulated by law and implemented
as a guideline, which is elaborated by the Federal Joint
Committee for hospital quality assurance in accordance
with Volume V of the Social Insurance Code (§137 SGB
V and §135a SGB V). Based on this regulation, the Hesse
State Hospital Law contains a provision that allows the
GQH to record such data legally. The publication of
aggregate quality assurance data has also been cleared
with the Hesse Data Protection Commissioner, so no data
protection problem arises here either [10,11].
Statistical analysis
Continuous variables were analysed by calculating the
median and mean value and the interquartile range
(25%-percentile and 75%-percentile). Nonparametric data
were analysed employing the Mann–Whitney U-test. For
comparing relative frequencies Chi-squared test was used.
All statistical analyses were performed with the PASW
Statistics 18, release version 18.0.2 (© SPSS, Inc., 2009,
Chicago, IL, http://www.spss.com) and SAS software,
version 9.2 of the SAS System for Windows (© 2008 SAS
Institute Inc., Cary, NC).
Results
Among 151,158 documented cases between 2004 and
2010 in the Hesse Stroke Registry 17,007 cases were
identified as juvenile (age < 56 years) and 15,997 had a
cerebrovascular event (91% ischaemic stroke or TIA, 9%
intracerebral haemorrhage) (Figure 1). In the sifap1
study 5023 subjects were included; 23.3% had TIA, 70.7%
brain infarction, and 5.6% haemorrhagic strokes.
The sex distribution in both groups was comparable
(males 59% sifap1 versus 60.5% GQH). There was an ob-
vious difference in the age distribution between the two
151158 cases of is chaemic stroke or TIA, bleedings and other
aetiologies documented in the Hesse stroke registry (2004-2010) 
1475 cases of intracerebral  
hemorrhage (9%)
14522 cases of ischemic stroke 
or TIA (91%)
17007 selected cases representing young patients 
134151 cases ≥56 years of age (89%) 
15997 selected cases with documented cerebrovascular event  
759 cases of documented subarachnoid hemorrhage 
251 cases without specific classification (e.g. CVT) 
9239 cases of ischemic stroke 
(64%)
5283 cases of TIA 
(36%)
Figure 1 Patients selection within the stroke registry of the Institute of quality assurance Hesse (GQH).
Table 1 Synopsis with methodological characteristics of the sifap1 study
Study design Observational prospective cross-sectional multicentre multinational (European) study
Study objectives
Primary objectives To determine the prevalence of Fabry disease in young stroke patients
Secondary objectives To describe patterns of stroke in young patients
Inclusion criteria
Age 18–55 years
Time since event Less than 3 months before inclusion into the study
Diagnosis Acute CVE of any aetiology (ischemic stroke, TIA, intracranial haemorrhage)
Verification of diagnosis Verification of brain infarction or haemorrhage byMRI scan.In case of negative MRI
diagnosis confirmed by stroke-experienced neurologist (more than 2 years of
experience in stroke and at least 6 years of experience in general neurology)
Diagnostic information MRI documentation availableDiagnostic procedures according to EUSI/ESO
recommendations
Ethics Written informed consent from patient or legalrepresentative according to local ethics
committeeregulations
Inclusion period April 2007 till January 2010
Number of participating countries 15
Number of centres 47
Number of included patients 5023
Overall inclusion rate in the 7 best recruiting centres 52.9%
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Figure 2 Age distribution stratified by age classes in sifap1 (n = 5023) versus GQH (n = 17007).
Table 2 Baseline characteristics, risk factors, and stroke
severity
sifap1
(n = 5023)
GQH
(n = 17007)
Sex (males) (n = 5023, sifap1) 59% 60.5%
Age (years); median and 25th-75th
percentile
46 (40-51) 49 (44-53)
Previous (symptomatic) cerebrovascular
event (n = 5022, sifap1)
16.8% 10.9%***
Event entities
TIA 22.3% 31.1%***a
Brain infarction 70.7% 54.3%
Primary haemorrhage 5.6% 8.7%
Others† 1.4% 5.9%
Missing cases 217 -
Vascular risk profile
Hypertension (n = 4994, sifap1) 47% 49%*
Diabetes (n = 4996, sifap1) 10% 13.3%***
Current smoking (n = 5022, sifap1) 41.4% 38.5%***
Stroke severity
NIH stroke scale (median;
25th-75th percentile)
3 (1-6)║ 3 (1-6)‡
Modified rankin scale (median;
25th-75th percentile)
2 (1-3)║ 2 (1-3)§
†consider subarachnoid haemorrhage and cerebral sinus or vein thrombosis.
║assessed within the first 48 hours.
‡assessed on admission.
§assessed one day after admission.
*p < 0.05.
**p < 0.01.
***p < 0.001.
athe test statistic was calculated by using all entity categories.
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http://www.biomedcentral.com/1471-2377/14/45groups (Figure 2). The proportion of younger patients in
sifap1 was higher, whereas in the age category 45 to
55 years a higher percentage of patients within GQH was
noted compared to sifap1 (72% versus 59.7%; Figure 2).
Brain infarctions totalled in sifap1 a higher proportion
of patients than in the GQH group (70.7% versus 54.3%,
p < 0.001). While the distribution of vascular risk factors
in the two groups revealed slightly higher percentages
for diabetes mellitus and hypertension in the GQH
group, the stroke severity as determined by NIHSS and
mRS were identical regarding median and interquartile
ranges (Table 2).
In the subgroups of patients with ischaemic stroke or
TIA the sex distribution remained similar as compared
in the total groups (59.4% males in sifap1 versus 61.2%
GQH, Table 3). Considering patients with ischaemic
stroke or TIA, the difference in age distribution per-
sisted between the two groups with a three years shift
(median 47 years sifap1 versus 50 years GQH). The pro-
portion of TIA patients was higher in GQH (36.4%) than
in sifap1 (24%); more patients with a previous stroke
were included in sifap1 (16.9% versus 11.9%). In the age
category of 45-55 years the proportion of patients
with hypertension was similar (58.2%) in both groups
(Table 3).
The distribution of stroke subtypes revealed a high
percentage of patients classified as having an ischaemic
stroke of other determined or undetermined cause in
the sifap1 study (Table 3). In older age groups (compar-
ing 45-55 years versus 18-44 years) higher rates of
strokes due to small artery occlusion (GQH: 21.8% ver-
sus 12.3% and Sifap 1: 17.2% versus 8.4%) and athero-
sclerosis (GQH: 26% versus 12.4% and sifap1: 21.8%
versus 8.4%) were obvious; rates of cardiac embolic
strokes (GQH: 11.4% versus 13.9% and sifap1: 13.3% ver-
sus 18%) and strokes of other determined cause (GQH:
7.8% versus 14.9% and sifap1: 12.8% versus 22%) lowered
from the young to the older age category in both popu-
lations (Table 3 and Figure 3).Discussion
The main difference between the sifap1 and the corre-
sponding GQH group represents the more left skewed
age distribution in the GQH group as compared to
sifap1: in sifap1 more younger patients were included,
while in the GQH a higher proportion of patients aged
Table 3 Subgroup of ischaemic strokes or TIA stratified by age groups (demographic characteristics, risk factors, and stroke subtypes)
Total groups Age 18-34 years Age 35-44 years Age 45-55 years
sifap1(n = 4467) GQH(n = 14522) sifap1(n = 563)
12.6%
GQH(n = 1049)
7.2%***
sifap1(n = 1224)
27.4%
GQH(n = 2962)
20.4%***
sifap1(n = 2680)
60%
GQH(n = 10511)
72.4%***
Sex (males); (n = 4467, Sifap1) 59.4% 61.2%* 42.8% 46.3% 57.9% 57.9% 63.5% 63.5%
Age (years); mean, median and 25th-75th
percentile (n = 4467, Sifap1)
44.747 (40-51) 47.5*** 50 (44-53) 28.329 (25-32) 28.4 29 (25-32) 40.541 (38-43) 40.6 41 (39-43) 50.150 (47-53) 51.4*** 51 (48-53)
Previous cerebrovascular event
(n = 4466, Sifap1)
16.9% 11.9%*** 12.8% 7.7%** 15.4% 8.2%*** 18.6% 13.3%***
Proportion of TIA (n = 4467, Sifap1) 24.0% 36.4%*** 21.8% 41.5%*** 25.1% 39.7%*** 23.9% 34.9%***
Vascular risk profile
Hypertension (n = 4439, Sifap1) 46.6% 49.5%** 13.1% 11.6% 36.7% 31.7%** 58.2% 58.2%
Diabetes mellitus (n = 4443, Sifap1) 10.3% 14.4%*** 2.0% 3.1% 7.7% 8.6% 13.3% 17.1%***
Current smoking (n = 4466, Sifap1) 42.5% 40.8%* 37.5% 33.5% 42.1% 41.3% 43.8% 41.5%
Stroke subtypes according to TOAST n = 4345 n = 14169 n = 555 n = 1006 n = 1201 n = 2902 n = 2589 n = 10261
Atherosclerosis 16.4% 22.3%***a 4.1% 8.8%***a 10.4% 13.6%***a 21.8% 26%***a
Cardiac embolic source 15.1% 12.1% 18.6% 15.3% 17.7% 13.4% 13.2% 11.4%
Small artery occlusion 13.7% 19.2% 6.3% 8.2% 9.5% 13.7% 17.2% 21.8%
Other determined cause 16.5% 9.8% 24.5% 16.7% 20.8% 14.3% 12.8% 7.8%
Undetermined cause 38.3% 36.7% 46.5% 51.0% 41.6% 45.0% 34.9% 33.0%
*p < 0.05.
**p < 0.01.
***p < 0.001.
athe test statistic was calculated by using all five TOAST classification categories.
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Figure 3 Stroke subtypes stratified by age sifap1 versus GQH.
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http://www.biomedcentral.com/1471-2377/14/4545-55 were evident. This result is in line with previous
investigations, revealing comparable differences when
considering the entire population of young stroke pa-
tients in sifap1 centres compared to those patients
included in sifap1 [7].
However, in both groups (sifap1 and GQH) the age
distribution is skewed to the left: when creating smaller
age categories the proportions of patients were higher in
older age groups (Figure 2). In accordance with previous
investigations in both populations higher percentages of
vascular risk factors in elderly patients were observed
[2,3,12,13]. In this context the markedly higher propor-
tion of vascular risk factors in the GQH registry might
partially be determined by the higher proportion of older
patients in the registry as compared to sifap1. In the
sifap1 study, which specifically addressed stroke in the
young, a selection bias for recruiting particularly younger
patients could be suspected. In contrast in the GQH this
phenomenon is of minor importance, as the registry
regards to the entirety of strokes without any restrictions.
In the subgroups of patients with ischaemic stroke or
TIA the difference in age might determine the distribu-
tion of aetiologies as well. In older aged patients lower
proportions of cardioembolic strokes, strokes of other
determined cause or undetermined cause were obvious,
whereas proportions of stroke causes, such as athero-
sclerosis and small artery occlusion were higher in older
aged patients. The higher age level in the GQH affected
differences in the prevalence of stroke aetiologies be-
tween sifap1 and GQH data (Figure 3). Nevertheless the
distributions of aetiologies in both collectives seem com-
parable with a consistent association between age and
prevalence differences. This underlines the reliability of
the data accumulated in the sifap1 study and GQH
registry, respectively.
In the subgroup of patients with ischaemic stroke or
TIA the proportion of previous cerebrovascular eventsin the sifap1 study was markedly higher than in the
GQH data (16.9% versus 11.9%). The proportion of TIAs
is higher in the GQH-data than in sifap1. Regarding
the very young subgroups (18-44 years), in sifap1 the
proportion of patients with a previous cerebrovascular
event doubled the corresponding value in GQH (14.5%
versus 7.7%).
In young stroke patients with a previous cerebrovascu-
lar event and predominantly without vascular risk fac-
tors and with unknown cause for stroke, considering
Fabry disease as a potential differential diagnosis appears
mandatory, and might facilitate the inclusion in sifap1 a
welcome option [14]. On the other hand previous cere-
brovascular events might be missed in a global registry
due to less rigorous requirements regarding imaging
procedures and data acquisition. For inclusion in the
sifap1 study a cerebral MRI scan was mandatory. In
the GQH registry in 73% of patients with ischaemic stroke
or TIA underwent the procedure during the acute treat-
ment (unpublished data considering patients (n = 4783)
documented 2009-2010 in the GQH registry; for these two
years a consistent documentation of cerebral MRI was
available). This might also determine the higher proportion
of patients diagnosed with a TIA in the GQH registry.
Comparing the entire populations, the proportion of
brain haemorrhages in the GQH stroke registry ranged
higher (8.7% versus 5.6%) than in sifap1. The restraint in
including bleedings in sifap1 might be also determined
by the nature of the study, as cerebral haemorrhages are
rarely accompanied by Fabry disease [15,16].
The evaluation of the disability data rendered similar
results in sifap1 and GQH; both scales (mRS, NIHSS)
showed identical median and interquartile values. With
regard to stroke severity, the populations are therefore
comparable. Considering that in clinical trials or obser-
vational studies severely disabled patients are less se-
lected for inclusion, due to difficulties in handling, in
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sion, concerning the stroke severity the sifap1 study is
adequately balanced with distributions approaching the
situation in the care delivery as reflected in the GQH
stroke registry.
Similarly to the stroke severity, the sex distribution is
comparable in both groups, with somewhat higher pro-
portions of women in sifap1. In older age the proportion
of males is higher than in younger age groups. Among
the oldest age range (45-55 years) the vascular disease
might preponderate in males more than in females, de-
termining more strokes related to a vascular burden
such as atherosclerotic strokes or strokes due to small
artery occlusion among males [3,17]. When including
patients in a clinical study addressing stroke or a rare
disease causing stroke the patient’s sex per se could not
be expected to influence on the behaviour regarding in-
clusion. Therefore the almost identical sex distribution
in both groups renders a reciprocal validation in the
reliability of the accumulated data in sifap1 and GQH,
respectively.
Conclusion
Differences in baseline characteristics between the sifap1
study and the GQH stroke registry were noted. They
were mainly determined by age. In these specific patient
groups including young strokes (≤55 years) the median
age in the sifap1 study was 3 years below the median in
the GQH. Stroke aetiologies determined by vascular bur-
den were more often present in older patients, whereas
undetermined stroke causes and stroke of other deter-
mined aetiologies occurred less frequent. Especially among
the young groups (18-44) high proportions of cryptogenic
strokes were evident in the sifap1 study as well as in the
GQH stroke registry (43% and 46%). Comparable sex dis-
tributions in sifap1 and GQH, in this particular case a fac-
tor robust against selection bias, underline the reliability of
the data accumulated in both collectives.
Sifap1 represents a pivotal study on young stroke
providing important information on distribution of
risk and etiologic factors. One of the novel findings
depicted in sifap1 is the high prevalence of vascular
risk factors in young stroke patients [2]. In this con-
text, the comparison with a comprehensive population
is of high relevance and need to be taken into consid-
eration when referring to sifap1. It indicates, that in a
general population of young strokes, even higher per-
centages of vascular risk factors (hypertension and
diabetes) and stroke aetiologies related to a vascular bur-
den (arteriosclerosis and small artery occlusion) might be
expected. It emphasises the need of new strategies in the
primary stroke prevention considering the substantial
contribution of vascular risk factors for causing strokes
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